Objective To evaluate response to low dose oxybutynin in children with nocturnal enuresis.
Materials and Methods Forty one out of 111 neurologically normal enuretic children who referred nephrology clinic in a 3- year period (2007–2009)received low dose oxybutynin (2.5–10 mg/day depending on the age) to define response to the drug in one and 3- month periods .No response, partially and full responses were defined as decreased in bed wetting in the rate of 0–49%, 50–89% and ≥90% respectively.
Results In first month of treatment, full, partial and no responses were reported in 3 (7.3%), 14 (34.1%) and 24 (58.6%) patients respectively. In non-responder patients 6 (25%) and 5) 20.8 % (patients had full and partial responses in 3-month period, whereas 13 (54.2%) had no response. Side effects of the drug were reported in 5 (12.2%) patients .Children with non-mono symptomatic nocturnal enuresis presented a better response to the drug than those with mono symptomatic nocturnal enuresis (75% versus 25%). There was no significant differences between age, gender, family history of enuresis and presence of absence of daytime urinary or bowel symptoms in responder and non-responder groups (p>0.05 for all).
Conclusion In the present study which is a clinical report study with no control group, there was 68.3% treatment benefit and 12 % risk (side effects of the drug) with low dose oxybutynin, so it may have a role in treating nocturnal enuresis especially patients with NMNE who experience adverse effects of the drug with standard treatment.